ConocoPhillips vs Humana Inc — how do they compare? ConocoPhillips trades at $133.5 (market cap $155.98B), while Humana Inc trades at $439.56 (market cap $47.61B). The key difference: ConocoPhillips is far larger — about 3.3× Humana Inc's market cap, and ConocoPhillips pays the higher dividend (2.59%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Humana Inc for 53 Days on average.
| COP | HUM | |
|---|---|---|
Market Cap | $155.98B | $47.61B |
Volume | 4,774,951 | 1,827,332 |
Sector | Energy | Health |
52-Week High | $141.22 | $409.85 |
52-Week Low | $85.66 | $163.67 |
Typical Hold Time | 79 Days | 53 Days |
Enterprise Value | $171.58B | $54.97B |
Dividend Yield | 2.59% | 0.89% |
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.19, up 3.74% with strong technical momentum and bullish moving averages. The company shows solid fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global announced October 1, 2026. Valuation metrics remain reasonable with P/E of 17.17 and EV/EBITDA of 6.17, while analyst consensus favors Buy ratings (75%) with a $154.75 price target.
Outlook remains positive given robust cash flow generation and strategic LNG expansion, though risks include oil price volatility and geopolitical exposure. The stock offers value with upside potential to analyst targets, but investors should monitor execution on international asset sales and energy market dynamics.
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →